In the last trading session, 20,042,043 shares of the VistaGen Therapeutics, Inc.(NASDAQ:VTGN) were traded, and its beta was 0.91. Most recently the company’s share price was $2.96, and it changed around $0.48 or 0.19% from the last close, which brings the market valuation of the company to $419.41 Million. VTGN currently trades at a discount to its 52-week high of $3, offering almost -1.35% off that amount. The share price’s 52-week low was $0.3, which indicates that the current value has risen by an impressive 89.86% since then. We note from VistaGen Therapeutics, Inc.’s average daily trading volume that its 10-day average is 12.75 Million shares, with the 3-month average coming to 3.9 Million.
VistaGen Therapeutics, Inc. stock received a consensus recommendation rating of Buy, based on a mean score of 1.5. If we narrow it down even further, the data shows that none out of 4 analysts rate the stock as a Sell; another but none rate it as Overweight. Among the rest, no body recommended VTGN as a Hold, whereas 4 deemed it a Buy, and no one rated it as Underweight. VistaGen Therapeutics, Inc. is expected to report earnings per share of -$0.04 for the current quarter.
VistaGen Therapeutics, Inc. (NASDAQ:VTGN): Trading Information
Instantly VTGN has showed a green trend with a performance of 19.35% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of $3.00- on Friday, Feb 19 increased the stock’s daily price by 1.33%. The company’s shares are currently up 0.53% year-to-date, but still up 0.4949 over the last five days. On the other hand, VistaGen Therapeutics, Inc. (NASDAQ:VTGN) is 0.27% up in the 30-day period. We can see from the shorts that 5.39 Million shares have been sold at a short interest cover period of 1.38 day(s).
The consensus price target as assigned by Wall Street analysts is $5.67, which translates to bears needing to increase their stock price by 91.55% from its current value. Analyst projections state that VTGN is forecast to be at a low of $5 and a high of $6. In order for the stock price to hit the forecast high, the stock would need to surge +102.7% from its current level, while the stock would need to crash 68.92% from its current level to reach the projected low.
VistaGen Therapeutics, Inc. (VTGN) projections and forecasts
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 45.6%. VistaGen Therapeutics, Inc. earnings are expected to increase by 44.2% in 2021, but the outlook is negative 0% per year for the next five years.
VistaGen Therapeutics, Inc. (NASDAQ:VTGN)’s Biggest Investors
Upon looking at major shareholders, it appears that insiders hold 4.48% of VistaGen Therapeutics, Inc. shares, and 7.53% of them are in the hands of institutional investors. The stock currently has a share float of 7.88%. VistaGen Therapeutics, Inc. stock is held by 29 institutions, with Franklin Resources, Inc. being the largest institutional investor. By Dec 30, 2020, it held 4.5% of the shares, which is about 6.24 Million shares worth $12.11 Million.
Vanguard Group, Inc. (The), with 1.4% or 1.95 Million shares worth $1.36 Million as of Sep 29, 2020, holds the second largest percentage of outstanding shares.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.